<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611492</url>
  </required_header>
  <id_info>
    <org_study_id>AOM12629_1</org_study_id>
    <nct_id>NCT02611492</nct_id>
  </id_info>
  <brief_title>A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults</brief_title>
  <acronym>GRAAPH2014</acronym>
  <official_title>A Phase III Study, Randomized, to Evaluate the Reduction of Chemotherapy Intensity in Association With Nilotinib (Tasigna®) in Philadelphia Chromosome-positive (Ph+) ALL of Young Adults (18-59 Years Old) (GRAAPH-2014)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Primary objective is to assess the non-inferiority of the experimental arm (arm B)
      compared to the control arm (arm A) in terms of Major Molecular Response (MMolR) after the
      4th cycle (MRD4) in patients aged 18-59 years old with de novo Philadelphia positive (Ph+)
      acute lymphoblastic leukemia (ALL)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Molecular Response (MMolR)</measure>
    <time_frame>4 cycles (4 months)</time_frame>
    <description>defined as a breakpoint cluster region (BCR)-Abelson (ABL) ratio &lt; 0.1% in the bone marrow sample of MRD4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission after cycle 1</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of treatment- and transplantation-related mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T315I mutation</measure>
    <time_frame>10 years</time_frame>
    <description>mutations will be assessed by Reverse transcription Quantitative Polymerase Chain Reaction (RQ-PCR) sequencing in case of progression or relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">265</enrollment>
  <condition>Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)
+ Post-SCT Maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Light Arm (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)
+ Post-SCT Maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_label>Light Arm (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_label>Light Arm (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aracytine (Ara C)</intervention_name>
    <description>Age&lt;45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age&gt;=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte Colony-Stimulating Factor (G-CSF)</intervention_name>
    <description>5µg/kg/d (SC) D6 until neutrophils &gt; 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_label>Light Arm (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depomedrol</intervention_name>
    <description>40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_label>Light Arm (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_label>Light Arm (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_label>Light Arm (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_label>Light Arm (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6 Mercaptopurine (6MP)</intervention_name>
    <description>60 mg/m2 per os, D1 to D14, interphase</description>
    <arm_group_label>Intensive Arm (A)</arm_group_label>
    <arm_group_label>Light Arm (B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient

          1. Whose blood and bone marrow explorations have been completed before the steroids
             prephase

          2. Aged 18-59 years old with newly-diagnosed non previously treated Ph+ ALL according to
             WHO 2008 criteria (confirmed diagnosis of the Philadelphia chromosome defined by the
             reciprocal translocation of chromosomes 9 and 22, t(9;22) and/or presence of the
             BCR-ABL molecular maker)

          3. With ≥ 20% bone marrow blasts

          4. With Eastern Cooperative Oncology Group (ECOG) Performans Status ≤ 3

          5. With or without central nervous system (CNS) or testis involvement

          6. Without evolving cancer (except basal cell carcinoma of the skin or &quot;in situ&quot;
             carcinoma of the cervix) or its chemo- or radio-therapy should be finished at least
             since 6 months.

          7. Having received no previous treatment for this hematological disease (including IT
             injection)

          8. Having signed written informed consent

          9. With efficient contraception for women of childbearing age (excluding estrogens and
             IUD)

         10. With health insurance coverage

         11. Who have received (or being receiving) the recommended steroid prephase.

        Note 1: Secondary ALL (antecedent of chemo- or radio-therapy) can be included Note 2: In
        case of high vascular risk (see section &quot;study management&quot;) the patient will not be able to
        receive nilotinib unless an ultra sound Doppler of the neck and lower limbs has been
        performed during the pre-phase and treatment validated by the medical coordinators of the
        protocol via the secretariat.

        Exclusion Criteria:

        Patient:

          1. Previously treated with Tyrosine Kinase Inhibitor (TKI)

          2. With another active malignancy

          3. With general or visceral contra-indication to intensive therapy (except if considered
             related to the ALL):

               1. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt; 2.5 x
                  upper limit of normal range (ULN)

               2. Total bilirubin &gt; 1.5 x ULN

               3. Creatinine &gt; 1.5 x ULN or creatinine clearance &lt;50 mL/mn

               4. Serum amylase or lipase &gt; 1.5 x ULN or antecedents of acute pancreatitis

          4. With heart failure, including at least one of the following criteria:

               1. Left ventricular ejection fraction (LVEF) &lt;50% or below the lowest normal
                  threshold, as determined by ECG or heart failure (NYHA grade III or IV)

               2. Impossibility to measure the QT interval on ECG

               3. Complete left bundle branch block

               4. Pacemaker

               5. Congenital long QT syndrome of known familial antecedents of long QT syndrome

               6. Antecedents or current ventricular or atrial tachyarrhythmia, clinically
                  significant

               7. Baseline bradycardia (&lt;50 bpm) clinically significant

               8. Corrected QT interval (QTc)&gt; 450 msec established on the mean of 3 baseline ECG

               9. Antecedents of myocardial infarct in the past 6 months

              10. Instable angor within the past 12 months

              11. Any heart condition clinically significant (i.e. congestive heart failure,
                  uncontrolled hypertension)

          5. Active uncontrolled infection, any other concurrent disease deemed to interfere with
             the conduct of the study as judged by the investigator

          6. Severe evolving infection, or known HIV or Human T-Lymphotropic Virus type I (HTLV1)
             seropositivity, or active infection by hepatitis B or C virus

          7. Pregnant (beta-HCG) or nursing woman

          8. Women of childbearing potential not willing to use an effective form of contraception
             during participation in the study and at least three months thereafter. Patient not
             willing to ensure not to beget a child during participation in the study and at least
             three months thereafter.

          9. Having received an investigational treatment or participation in another trial within
             30 days prior to entering this study.

         10. Not able to bear with the procedures or the frequency of visits planned in the trial.

         11. Unable to consent, under tutelage or curators, or judiciary safeguard
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hervé Dombret, MDPhD</last_name>
    <phone>+33 (0)1 57 27 68 47</phone>
    <email>herve.dombret@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Véronique Lhéritier</last_name>
    <phone>+33(0)4 78 86 22 39</phone>
    <email>veronique.lheritier@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Dombret, MDPhD</last_name>
      <phone>+33 (0)1 57 27 68 47</phone>
      <email>herve.dombret@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

